Wire · opportunities
FDA Approval of Essential Thrombocythemia Drug is “Important Milestone”
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
The FDA approved ropeginterferon alfa-2b (BESREMi) for adults with essential thrombocythemia, making it the second FDA-approved therapy for the disease. The approval was supported by the SURPASS-ET trial, which showed superior durable responses and reduced thromboembolic events compared to anagrelide.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 31 Aug 2026 and 2 Sep 2026.
◆ ◆ The Wire takeaway
You must update your clinical approach and patient communications now that the FDA has approved a new therapy for essential thrombocythemia with proven better outcomes. This opens a fresh opportunity to differentiate your treatment offerings and capture patients seeking improved chronic leukemia care.
◆ Coverage
10 sources · first reported 31 Aug 2026 · latest 2 Sep 2026
◆ Related on Wire
◆ Topics